SCHEMBL25656149

SCHEMBL25656149

Cc1cc2ncnc(N3CCCN(CCNS(=O)(=O)NC(=O)OC(C)(C)C)CC3)c2cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 7/20 0.50
SIRT2 Q8IXJ6 4/20 0.43
SIRT1 Q96EB6 4/20 0.43
SIRT3 Q9NTG7 4/20 0.43
AURKA O14965 2/20 0.40
PDGFRB P09619 7/20 0.37
CSF1R P07333 2/20 0.37
KIT P10721 2/20 0.37
FLT3 P36888 2/20 0.37
PLK4 O00444 1/20 0.37
GAK O14976 1/20 0.37
EPHB6 O15197 1/20 0.37
STK10 O94804 1/20 0.37
EGFR P00533 1/20 0.37
NTRK1 P04629 1/20 0.37
LCK P06239 1/20 0.37
FGFR1 P11362 1/20 0.37
SRC P12931 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25656150 0.95 ENPP1 (0.57) ENPP1SIRT2SIRT1SIRT3AURKA
SCHEMBL25656142 0.92 ENPP1 (0.46) ENPP1SIRT2SIRT1SIRT3AURKA
SCHEMBL23762509 0.90 ENPP1 (0.63) ENPP1AURKAPDGFRBCSF1RKIT
SCHEMBL30117243 0.90 ENPP1 (0.63) ENPP1AURKAPDGFRBCSF1RKIT
SCHEMBL25656169 0.87 ENPP1 (0.59) ENPP1SIRT2SIRT1SIRT3AURKA
SCHEMBL23762473 0.85 ENPP1 (0.71) ENPP1AURKAPDGFRBCSF1RKIT
SCHEMBL25656168 0.85 ENPP1 (0.58) ENPP1AURKAPDGFRBKITPDGFRA
SCHEMBL25656155 0.83 ENPP1 (0.54) ENPP1PDGFRB
SCHEMBL25656098 0.82 ENPP1 (0.50) ENPP1SIRT2SIRT1SIRT3AURKA
SCHEMBL25656151 0.81 ENPP1 (0.69) ENPP1SIRT2SIRT1SIRT3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 ENPP1 1/4885SIRT2 1843/4885SIRT1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.